Ratings coverage on Celldex Therapeutics Inc (NASDAQ: CLDX), Immunomedics Incorporated (NASDAQ: IMMU), YPF Sociedad Anonima (NYSE: YPF), CVR Partners (NYSE: UAN) and Cintas (NASDAQ: CTAS) was initiated by analysts this week.
Oppenheimer initiated coverage on Celldex Therapeutics Inc (CLDX). They placed an “outperform” rating and a price target of $6.00 on the company.
Oppenheimer initiated coverage on shares of Immunomedics Incorporated (IMMU). They placed an “outperform” rating and a price target of $6.00 on the company.
Raymond James (NYSE:RJF) initiated coverage on YPF Sociedad Anonima (YPF). They placed an “outperform” rating on the company.
Goldman Sachs (NYSE:GS) initiated coverage on shares of CVR Partners (UAN). They placed a “neutral” rating on the company.
Stifel Nicolaus initiated coverage on Cintas (CTAS). They placed a “hold” rating and a price target of $30.70 on the company.
Showing posts with label Immunomedics. Show all posts
Showing posts with label Immunomedics. Show all posts
Saturday, May 21, 2011
Friday, May 20, 2011
Coverage on (JPM) (IMMU) (MAKO) (MMI) Initiated
Coverage on shares of JPMorgan Chase (NYSE:JPM), Immunomedics (NASDAQ:IMMU), MAKO Surgical (NASDAQ:MAKO) and Motorola Mobility (NYSE:MMI) was initiated by analysts.
Cowen initiated coverage on Immunomedics (IMMU), starting them off with an "Outperform" rating.
Stifel Nicolaus initiated coverage on JPMorgan Chase (JPM), starting them off with a "Hold" rating.
William Blair initiated coverage on MAKO Surgical (MAKO), starting them off with an "Outperform " rating.
ThinkEquity initiated coverage on Motorola Mobility (MMI), starting them off with a "Buy" rating.
Cowen initiated coverage on Immunomedics (IMMU), starting them off with an "Outperform" rating.
Stifel Nicolaus initiated coverage on JPMorgan Chase (JPM), starting them off with a "Hold" rating.
William Blair initiated coverage on MAKO Surgical (MAKO), starting them off with an "Outperform " rating.
ThinkEquity initiated coverage on Motorola Mobility (MMI), starting them off with a "Buy" rating.
Tuesday, May 17, 2011
Coverage on (DGII) (HRC) (IMMU) (IRM) (KERX) Initiated
Coverage on Digi International Inc. (NASDAQ: DGII), Hill-Rom Holdings, Inc. (NYSE: HRC), Immunomedics Incorporated (NASDAQ: IMMU), Iron Mountain Incorporated (NYSE: IRM) and Keryx Biopharmaceuticals Inc (NASDAQ: KERX) was initiated by analysts.
Feltl & Co. initiated coverage on Digi International Inc. (DGII). They placed a “buy” rating and a price target of $13.25 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Hill-Rom Holdings, Inc. (HRC). They placed a “neutral” rating on the company.
Oppenheimer initiated coverage on Immunomedics Incorporated (IMMU). They placed an “outperform” rating and a price target of $6.00 on the company.
Stifel Nicolaus initiated coverage on Iron Mountain Incorporated (IRM). They placed a “buy” rating and a price target of $39.00 on the company.
Oppenheimer initiated coverage on Keryx Biopharmaceuticals Inc (KERX). They placed an “outperform” rating and a price target of $7.00 on the company.
Feltl & Co. initiated coverage on Digi International Inc. (DGII). They placed a “buy” rating and a price target of $13.25 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Hill-Rom Holdings, Inc. (HRC). They placed a “neutral” rating on the company.
Oppenheimer initiated coverage on Immunomedics Incorporated (IMMU). They placed an “outperform” rating and a price target of $6.00 on the company.
Stifel Nicolaus initiated coverage on Iron Mountain Incorporated (IRM). They placed a “buy” rating and a price target of $39.00 on the company.
Oppenheimer initiated coverage on Keryx Biopharmaceuticals Inc (KERX). They placed an “outperform” rating and a price target of $7.00 on the company.
Subscribe to:
Posts (Atom)